<code id='AB4E25ECD2'></code><style id='AB4E25ECD2'></style>
    • <acronym id='AB4E25ECD2'></acronym>
      <center id='AB4E25ECD2'><center id='AB4E25ECD2'><tfoot id='AB4E25ECD2'></tfoot></center><abbr id='AB4E25ECD2'><dir id='AB4E25ECD2'><tfoot id='AB4E25ECD2'></tfoot><noframes id='AB4E25ECD2'>

    • <optgroup id='AB4E25ECD2'><strike id='AB4E25ECD2'><sup id='AB4E25ECD2'></sup></strike><code id='AB4E25ECD2'></code></optgroup>
        1. <b id='AB4E25ECD2'><label id='AB4E25ECD2'><select id='AB4E25ECD2'><dt id='AB4E25ECD2'><span id='AB4E25ECD2'></span></dt></select></label></b><u id='AB4E25ECD2'></u>
          <i id='AB4E25ECD2'><strike id='AB4E25ECD2'><tt id='AB4E25ECD2'><pre id='AB4E25ECD2'></pre></tt></strike></i>

          knowledge

          knowledge

          author:explore    Page View:2872
          Astrida Schaeffer
          Since February 2022, Astrida Schaeffer has driven about 160 miles round trip every other week to Brigham and Women’s Hospital in Boston, where researchers are testing an intravenous drug they hope will prevent the onset of Alzheimer’s disease symptoms, or at least delay them. Suzanne Kreiter/The Boston Globe

          Alzheimer’s disease has killed at least three women in Astrida Schaeffer’s family over two generations, leaving her feeling helpless and bereft.

          The first was her Polish-born maternal grandmother, who began showing symptoms when Schaeffer started college in 1981 and died seven years later. Then came her mother, a onetime Fulbright Scholar and high school language teacher who had been fluent in five languages but lost the ability to speak. She died in 2019. Last year, the disease killed Schaeffer’s mother’s sister, a former lab technician for Johnson & Johnson.

          advertisement

          Schaeffer, a 59-year-old costume historian in North Berwick, Maine, has no symptoms of Alzheimer’s. But in 2021 her family history led her to apply to join a clinical trial testing a drug on people at risk for developing them. To participate, volunteers couldn’t have cognitive impairment. But they needed to test positive for a biomarker that put them at higher risk for mental decline ― deposits of a sticky toxic protein in the brain called beta-amyloid that is a hallmark of the disease.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more
          Former medical device CEO who sold dummy, plastic parts convicted of fraud
          Former medical device CEO who sold dummy, plastic parts convicted of fraud

          BRENDANSMIALOWSKI/AFPviaGettyImagesANewYorkjuryonWednesdayconvictedtheformerCEOofStimwave,acompanyth

          read more
          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more

          The problem with charging patients to message their doctors

          AdobeThinkingaboutmessagingyourphysicianaboutaweirdrash?Youmaywanttoholdoffonit.Somehospitalsystemsh